Global orphan drugs market led by Roche's rituximab
The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR) of 9.6% between 2005 and 2011, hitting a market value of $8.63 billion by the end of 2011, according to a new report added to the offering of Companiesandmarkets.com. It is forecast, however, that the orphan drugs market will witness near flat sales growth between 2011 and 2017.
The prize for the top selling drug went to rituximab, an oncology treatment sold by Swiss drug major Roche (ROG: SIX) which sell it under the trade name Rituxan. This drug has present day peak sales value of $7 billion and a discounted peak value of $154 billion, the report notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze